HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ken Suzawa Selected Research

Therapeutics

2/2024Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.
1/2024PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer.
10/2022Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer-associated fibroblast.
9/2021Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Locally Advanced Non-small-cell Lung Cancer Treated with Trimodality Therapy.
1/2021The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
1/2021Chronic Lung Injury After Trimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer.
12/2020RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
12/2020Prognostic nutrition index affects the prognosis of patients undergoing trimodality therapy for locally advanced non-small cell lung cancer.
1/2020MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions.
1/2020Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based combined therapy in non-small cell lung cancer.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ken Suzawa Research Topics

Disease

30Neoplasms (Cancer)
05/2024 - 03/2014
22Lung Neoplasms (Lung Cancer)
04/2024 - 03/2015
18Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2024 - 01/2014
7Neoplasm Metastasis (Metastasis)
02/2024 - 01/2018
4Sarcoma (Soft Tissue Sarcoma)
12/2023 - 01/2021
4Breast Neoplasms (Breast Cancer)
11/2021 - 01/2017
3Bronchiolitis Obliterans Syndrome
11/2023 - 02/2022
2Radiation Pneumonitis
03/2024 - 08/2020
2Adenocarcinoma of Lung
02/2024 - 01/2020
2Primary Graft Dysfunction
02/2024 - 10/2018
2Lymphatic Metastasis
10/2023 - 01/2022
2Pulmonary Fibrosis (Fibrosing Alveolitis)
04/2023 - 01/2021
2Ischemia
11/2022 - 10/2021
2Interstitial Lung Diseases (Interstitial Lung Disease)
11/2022 - 01/2021
2Lung Injury
10/2021 - 01/2021
1Critical Illness (Critically Ill)
05/2024
1Postoperative Hemorrhage
04/2024
1Acute Lung Injury
02/2024
1Sepsis (Septicemia)
02/2024
1Carcinoma (Carcinomatosis)
01/2024
1Leiomyosarcoma
12/2023
1Adenocarcinoma
10/2023
1Hemorrhage
01/2023
1Melanoma (Melanoma, Malignant)
09/2022
1Reperfusion Injury
10/2021
1Castleman Disease (Castleman's Disease)
09/2021
1Fistula
02/2021
1Fibrosis (Cirrhosis)
01/2021
1Idiopathic Pulmonary Fibrosis
01/2021
1Inflammation (Inflammations)
01/2021
1Persistent Infection
01/2021
1Pulmonary Aspergillosis
08/2020

Drug/Important Bio-Agent (IBA)

15Tyrosine Kinase InhibitorsIBA
02/2024 - 03/2015
6ErbB Receptors (EGF Receptor)IBA
02/2024 - 03/2015
5Proteins (Proteins, Gene)FDA Link
09/2022 - 12/2016
5human ERBB2 proteinIBA
11/2021 - 01/2017
4Biomarkers (Surrogate Marker)IBA
05/2024 - 10/2018
4AfatinibIBA
05/2018 - 10/2015
3Messenger RNA (mRNA)IBA
01/2022 - 01/2017
2CatecholaminesIBA
04/2024 - 03/2014
2histidine-rich proteinsIBA
02/2024 - 09/2022
2PeriostinIBA
12/2023 - 12/2023
2MicroRNAs (MicroRNA)IBA
04/2023 - 01/2017
2Trastuzumab (Herceptin)FDA Link
11/2021 - 01/2017
2Monoclonal AntibodiesIBA
10/2021 - 09/2021
2Carrier Proteins (Binding Protein)IBA
10/2021 - 12/2016
2Phosphotransferases (Kinase)IBA
12/2020 - 01/2018
2neratinibIBA
03/2020 - 03/2019
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2018 - 12/2016
1Indicators and Reagents (Reagents)IBA
05/2024
1Epinephrine (Adrenaline)FDA LinkGeneric
04/2024
1Adrenergic Agents (Adrenergic Drugs)IBA
04/2024
1EnzymesIBA
04/2024
1Glycoproteins (Glycoprotein)IBA
02/2024
1Plasminogen Activator Inhibitor 1IBA
01/2024
1CrizotinibIBA
01/2024
1RNA (Ribonucleic Acid)IBA
12/2023
1AntibodiesIBA
12/2023
1tranilastIBA
10/2022
1osimertinibIBA
10/2022
1AZD 6244IBA
10/2022
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
09/2022
1Chemotactic FactorsIBA
09/2022
1Blood Proteins (Serum Proteins)IBA
09/2022
1Keratin-19 (Keratin 19)IBA
01/2022
1Nucleic AcidsIBA
01/2022
1Ado-Trastuzumab EmtansineIBA
11/2021
1ChromatinIBA
10/2021
1HMGB1 Protein (HMG1)IBA
10/2021
1HMGB ProteinsIBA
10/2021
1salicylhydroxamic acid (SHAM)IBA
10/2021
1Mitogen-Activated Protein KinasesIBA
10/2021
1ChemokinesIBA
10/2021
1CytokinesIBA
10/2021
1Interleukin-6 (Interleukin 6)IBA
09/2021
1EnbucrilateIBA
02/2021
1EquolIBA
01/2021
1TamoxifenFDA LinkGeneric
01/2021
1indium-bleomycinIBA
01/2021
1Neutralizing AntibodiesIBA
01/2021
1Dihydrotachysterol (AT 10)IBA
01/2021
1IsoflavonesIBA
01/2021
1Hormones (Hormone)IBA
01/2021
1cabozantinibIBA
12/2020
1agerafenibIBA
12/2020
1LY3009120IBA
05/2020
1Dasatinib (BMS 354825)FDA Link
03/2020

Therapy/Procedure

16Therapeutics
02/2024 - 01/2016
9Lung Transplantation
05/2024 - 10/2018
7Chemoradiotherapy
03/2024 - 04/2015
4Adjuvant Chemotherapy
03/2024 - 08/2020
4Metastasectomy
12/2023 - 01/2021
3Operative Time
04/2024 - 01/2023
2Molecular Targeted Therapy
10/2022 - 03/2020
1Drug Therapy (Chemotherapy)
10/2023
1Thoracotomy
10/2023
1Mechanical Ventilators (Ventilator)
11/2022
1Thymectomy
07/2022
1Intravenous Administration
10/2021
1Pneumonectomy (Lung Volume Reduction)
02/2021